Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Bayer acquires rights in Puhe BioPharma cancer drug candidate
Details : Under the licensing agreement, Bayer obtains an exclusive worldwide license to develop, manufacture and commercialize the MTA-cooperative BAY 3713372, PRMT5 inhibitor.
Product Name : BAY 3713372
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 26, 2025